A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Completed · Phase 2
Conditions studied: Multiple Myeloma
In brief
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
Key facts
- Study ID
- NCT00051116
- Run by
- Celgene Corporation
- People needed
- 100
- Starts
- 2002-05-01
- Expected to finish
- 2006-10-01
- Last updated by the study team
- 2009-09-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Myeloma Institute University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.